 |
CLAUDIO GANDOLFO
Docente a contratto
Dipartimento di Economia "Marco Biagi"
|
Home |
Curriculum(pdf) |
Didattica |
Pubblicazioni
2022
- Guidelines for Vascular Anomalies by the Italian Society for the study of Vascular Anomalies (SISAV)
[Articolo su rivista]
Stillo, F.; Mattassi, R.; Diociaiuti, A.; Neri, I.; Baraldini, V.; Dalmonte, P.; Amato, B.; Ametrano, O.; Amico, G.; Bianchini, G.; Campisi, C.; Cattaneo, E.; Causin, F.; Cavalli, R.; Colletti, G.; Corbeddu, M.; Coppo, P.; De Fiores, A.; Di Giuseppe, P.; El Hachem, M.; Esposito, F.; Fulcheri, E.; Gandolfo, C.; Grussu, F.; Guglielmo, A.; Leuzzi, M.; Manunza, F.; Moneghini, L.; Monzani, N. A.; Nicodemi, E. M.; Occella, C.; Orso, M.; Pagella, F. G.; Paolantonio, G.; Pasetti, F.; Rollo, M.; Ruggiero, F.; Santecchia, L.; Spaccini, L.; Taurino, M.; Vaghi, M.; Vercellio, G.; Zama, M.; Zocca, A.; Aguglia, M.; Castronovo, E. L.; De Lorenzi, E.; Fontana, E.; Gusson, E.; Lanza, J.; Lizzio, R.; Mancardi, M. M.; Rosina, E.; Chiti, D.; Lugli, M.; Maleti, O.
abstract
2021
- Hepatitis C Virus Core Antigen (HCVAg): An affordable assay to monitor the efficacy of treatment in DAAs era
[Articolo su rivista]
Rossetti, B.; Loggi, E.; Raffaelli, C. S.; Mercinelli, S.; Gandolfo, C.; Savellini, G. G.; Galli, S.; Vitale, G.; Di Donato, R.; Vukotic, R.; Grandini, E.; Margotti, M.; Guarneri, V.; Furlini, G.; Re, M. C.; de Luca, A.; Andreone, P.; Galli, C.; Cusi, M. G.
abstract
Hepatitis C virus (HCV) Core Antigen (HCVAg) and HCV-RNA were tested in 962 plasma/serum samples from 180 patients during Direct Antiviral Agents (DAAs) treatment and at follow-up. One hundred and eighty individuals were included: 71% carried advanced fibrosis and 43% were treatment-experienced. A Sustained Virological Response (SVR) was achieved in 166/180 (92%) individuals: 96/102 (94.1%) naïve and 70/78 (89.7%) treatment-experienced (p=0.20). The baseline median levels of HCV-RNA and HCVAg were not significantly different between individuals achieving SVR (5.92 x 105 IU/mL, IQR 5.4-6.4, and 3,417 fmol/L, 2,900-3,795) and those without SVR (6.06 x 105 IU/mL, 5.63-6.57, and 3,391 fmol/L, 2,828-4,077). The HCV-RNA vs. HCVAg assays results showed a fair correlation with an overall moderate qualitative agreement (kappa=0.52). Among treatment-failed individuals, at failure 100% of the assays results were positive for both techniques, with HCV-RNA median value 3.09 x 105 IU/mL (2.10-29.09) and HCVAg median value 1570.28 fmol/L (360.15-9317.67). Undetectable HCV-RNA at EOT showed sensitivity 54%, specificity 100%, negative predictive value (NPV) 93% and positive predictive value (PPV) 100%. Undetectable HCVAg at EOT showed sensitivity 74%, specificity 100%, NPV 97% and PPV 100%. The operative and economic advantages of the HCVAg support the alternative use of HCVAg to monitor DAAs treatment outcome.